Ephrin-A4產(chǎn)品信息
英文名稱：Ephrin-A4
中文名稱：肝配蛋白A4
靶點別稱：EFNA4
物種：Human
屬性：Protein
標記：Unconjugated
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Ephrin-A4分子背景
Ephrin-A4 (EFNA4) is also known as EPH-related receptor tyrosine kinase ligand 4 (LERK4), EPLG4, which belongs to the ephrin family. EFNA4 contains one ephrin RBD (ephrin receptor-binding) domain. EFNA4 is cell surface GPI-bound ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. EFNA4 binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. EFNA4 may play a role in the interaction between activated B-lymphocytes and dendritic cells in tonsils.
關鍵字： Ephrin-A4;Ephrin-A4蛋白;EFNA4蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領域提供關鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學等。